These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26321015)

  • 1. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
    Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
    J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Wu X; Chapiro J; Malhotra A; Kothary N
    J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
    Lokken RP; Fidelman N; Kolli KP; Kerlan RK
    J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Facciorusso A; Mariani L; Sposito C; Spreafico C; Bongini M; Morosi C; Cascella T; Marchianò A; Camerini T; Bhoori S; Brunero F; Barone M; Mazzaferro V
    J Gastroenterol Hepatol; 2016 Mar; 31(3):645-53. PubMed ID: 26331807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
    Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
    J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
    Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
    J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
    J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
    Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
    J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.